Burning Rock Biotech Sustainability Profile
Burning Rock Biotech, a leading player in the biotechnology sector, is headquartered in China and operates extensively across Asia and beyond. Founded in 2014, the company has rapidly established itself as a pioneer in precision oncology, focusing on innovative genomic testing solutions that enhance cancer diagnosis and treatment. The firm’s core offerings include comprehensive genomic profiling and liquid biopsy services, which are distinguished by their accuracy and efficiency. Burning Rock Biotech's commitment to advancing personalised medicine has positioned it as a key contributor to the global fight against cancer, earning recognition for its cutting-edge technology and robust research capabilities. With a strong market presence and notable achievements in regulatory approvals, Burning Rock Biotech continues to drive advancements in the field, making significant strides in improving patient outcomes through tailored therapeutic strategies.
DitchCarbon Score
How does Burning Rock Biotech's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Burning Rock Biotech's score of 44 is higher than 62% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Burning Rock Biotech's reported carbon emissions
As of the latest available data, Burning Rock Biotech, headquartered in China, has not reported any specific carbon emissions figures. However, the company has established ambitious climate commitments through the Science Based Targets initiative (SBTi). Burning Rock Biotech is committed to achieving net-zero greenhouse gas emissions across its entire value chain by 2050. The company has set near-term targets to reduce absolute Scope 1 and Scope 2 greenhouse gas emissions by 42% by 2030, using 2022 as the baseline year. Additionally, it aims to increase its annual active sourcing of renewable electricity from 0% in 2022 to 100% by 2030. For Scope 3 emissions, the company has committed to a 25% reduction by 2030 from the same baseline year. In the long term, Burning Rock Biotech aims to reduce absolute Scope 1 and Scope 2 emissions by 90% by 2050, alongside a similar 90% reduction target for Scope 3 emissions by the same year. These targets reflect the company's alignment with the 1.5°C climate goal, demonstrating a strong commitment to sustainability and climate action.
How Carbon Intensive is Burning Rock Biotech's Industry?
How Carbon Intensive is Burning Rock Biotech's Location?
Burning Rock Biotech's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Burning Rock Biotech has established climate goals through participation in recognized frameworks and target-setting initiatives. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
